MAM
AGIO icon

Meeder Asset Management’s Agios Pharmaceuticals AGIO Stock Holding History

Meeder Asset Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,871
Closed -$86K – 1126
2021
Q3 		$86K Sell
1,871
-3,190
-63% -$154K ﹤0.01% 940
2021
Q2 		$279K Buy
5,061
+4,998
+7,933% +$279K 0.01% 655
2021
Q1 		$3K Hold
63
– – ﹤0.01% 1957
2020
Q4 		$3K Hold
63
– – ﹤0.01% 1330
2020
Q3 		$2K Sell
63
-102
-62% -$4.47K ﹤0.01% 1793
2020
Q2 		$8K Sell
165
-10
-6% -$463 ﹤0.01% 1378
2020
Q1 		$6K Buy
175
+26
+17% +$1.2K ﹤0.01% 1696
2019
Q4 		$7K Buy
149
+14
+10% +$529 ﹤0.01% 1668
2019
Q3 		$4K Buy
135
+84
+165% +$3.48K ﹤0.01% 1805
2019
Q2 		$3K Buy
+51
New +$2.73K ﹤0.01% 1779
2017
Q3 		– Sell
-63
Closed -$3K – 1615
2017
Q2 		$3K Sell
63
-28
-31% -$1.43K ﹤0.01% 1307
2017
Q1 		$5K Buy
+91
New +$4.36K ﹤0.01% 1052
2016
Q4 		– Sell
-172
Closed -$9K – 972
2016
Q3 		$9K Buy
+172
New +$7.49K ﹤0.01% 711

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Meeder Asset Management's AGIO Position: Q4 2021 in Review

Meeder Asset Management sold out of Agios Pharmaceuticals (AGIO) in Q4 2021, closing a stake of 1,871 shares — an estimated $86K sold.

Meeder Asset Management first reported a position in AGIO in Q3 2016 and held it in 13 quarters. The position peaked at $279K in Q2 2021. 160 funds tracked by Wall St. Rank hold AGIO as of Q4 2021.

  • Meeder Asset Management reported no remaining Agios Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Meeder Asset Management sold 1,871 Agios Pharmaceuticals shares in Q4 2021, an estimated $86K.
  • Meeder Asset Management first reported a position in Agios Pharmaceuticals in Q3 2016 and held it in 13 quarters.
  • Meeder Asset Management's Agios Pharmaceuticals position peaked at $279K in Q2 2021.
  • 160 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2021.

Based on Meeder Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.